Use of Aminoglycosides in Treatment of Infections Due to Intracellular Bacteria

Maurin, Max; Raoult, Didier

doi:10.1128/aac.45.11.2977-2986.2001

Cited by 113 publications

(76 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The linear increase in intracellular accumulation of the antibiotic with extracellular concentration suggested that the pinnocytosis proposed for GEN entrance [53] was not a saturated process, even at the high concentrations studied. Previous works performed in macrophages using a lower concentration of antibiotic (18 µg/mL), obtained higher I/E ratios, between 0.3-1.0 [50] compared to our ratio (0.001). However, different cell lines, incubation times and antibiotic concentrations were used.…”

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 47%

“…However, different cell lines, incubation times and antibiotic concentrations were used. Besides, the washing of cell monolayers to remove extracellular antibiotic, potentially underestimates antibiotic cell uptake since most antibiotics reemerge from the cell very rapidly during the washing procedure [50]. Other studies performed in fibroblasts had shown that after the incubation of high antibiotic concentrations (500 and 100 µg/mL) for several days, an 9 accumulation of the drug occurs with I/E ratios of 6.…”

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 99%

“…Aminoglycosides have shown such limited intracellular activity compared to their strong bactericidal potential in extracellular medium [50] that they have been used in vitro to eliminate extracellular bacteria without compromising intracellular survival [51,52]. Nevertheless, some authors have observed that aminoglycosides are readily incorporated into phagocytes when these cells are in contact for prolonged periods [50].…”

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 99%

“…Nevertheless, some authors have observed that aminoglycosides are readily incorporated into phagocytes when these cells are in contact for prolonged periods [50].…”

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 99%

See 3 more Smart Citations

Chemical and Biological Factors in the Control of Brucella and Brucellosis

Gamazo¹,

Lecaroz²,

Prior³

et al. 2006

CDD

View full text Add to dashboard Cite

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 47%

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 99%

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 99%

“…Nevertheless, some authors have observed that aminoglycosides are readily incorporated into phagocytes when these cells are in contact for prolonged periods [50].…”

Section: Gentamicin Biodisponibility and Drug Delivery Systemsmentioning

confidence: 99%

See 2 more Smart Citations

Chemical and Biological Factors in the Control of Brucella and Brucellosis

Gamazo¹,

Lecaroz²,

Prior³

et al. 2006

CDD

View full text Add to dashboard Cite

“…However, water-soluble quinolone and macrolide antibiotics, such as clindamycin, levofloxacin, etc. attain higher intracellular concentrations as opposed to extracellular concentrations [210][211][212]. Mycobacterium tuberculosis binds to and internalizes in the alveolar macrophages as a survival mechanism, and hence is very difficult to eradicate completely.…”

Section: Non-specific Targetingmentioning

confidence: 99%

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Merchant

Buckton²,

Taylor³

et al. 2016

CPD

View full text Add to dashboard Cite

Pulmonary infections may be fatal especially in immunocompromised patients and patients with underlying pulmonary dysfunction, such as those with cystic fibrosis, chronic obstructive pulmonary disorder, etc. According to the WHO, lower respiratory tract infections ranked first amongst the leading causes of death in 2012, and tuberculosis was included in the top 10 causes of death in low income countries, placing a considerable strain on their economies and healthcare systems. Eradication of lower respiratory infections is arduous, leading to high healthcare costs and requiring higher doses of antibiotics to reach optimal concentrations at the site of pulmonary infection for protracted periods. Hence direct inhalation to the respiratory epithelium has been investigated extensively in the past decade, and seems to be an attractive approach to eradicate and hence overcome this widespread problem. Moreover, engineering inhalation formulations wherein the antibiotics are encapsulated within nanoscale carriers could serve to overcome many of the limitations faced by conventional antibiotics, like difficulty in treating intracellular pathogens such as mycobacteria spp. and salmonella spp., biofilmassociated pathogens like Pseudomonas aeruginosa and Staphylococcus aureus, passage through the sputum associated with disorders like cystic fibrosis and chronic obstructive pulmonary disorder, systemic side effects following oral/parenteral delivery and inadequate concentrations of antibiotic at the site of infection leading to resistance. Encapsulation of antibiotics in nanocarriers may help in providing a protective environment to combat antibiotic degradation, confer controlled-release properties, hence reducing dosing frequency, and may increase uptake via specific and non-specific targeting modalities. Hence nanotechnology combined with direct administration to the airways using commercially available delivery devices, is a highly attractive formulation strategy to eradicate microorganisms from the lower respiratory tract, which might otherwise present opportunities for multi-drug resistance.

show abstract

Antibacterial Agents

Lewis,

Bush

2023

ClinMicroNow

View full text Add to dashboard Cite

Antimicrobial chemotherapy has played a vital role in the treatment of human infectious diseases since the discovery of penicillin in the 1920s. This chapter provides an overview of the antibacterial agents currently marketed in the United States, with major emphasis on their mechanisms of action, spectra of activity, important pharmacologic parameters, and toxicities. The major antibacterial action of penicillins is derived from their ability to inhibit multiple bacterial enzymes, namely, penicillin‐binding proteins (PBPs), that catalyze the last steps of peptidoglycan synthesis. The penicillins have antibacterial activity against most Gram‐positive and many Gram‐negative and anaerobic organisms. Like the penicillins, cephalosporins act by binding to PBPs of susceptible organisms, thereby interfering with the synthesis of peptidoglycan of the bacterial cell wall. Clavulanic acid is a naturally occurring weak antimicrobial agent found initially in cultures of Streptomyces clavuligerus . Streptomycin, neomycin, kanamycin, tobramycin, and gentamicin are naturally occurring aminoglycosides.

show abstract

Use of Aminoglycosides in Treatment of Infections Due to Intracellular Bacteria

Cited by 113 publications

References 171 publications

Chemical and Biological Factors in the Control of Brucella and Brucellosis

Chemical and Biological Factors in the Control of Brucella and Brucellosis

A New Era of Pulmonary Delivery of Nano-antimicrobial Therapeutics to Treat Chronic Pulmonary Infections

Antibacterial Agents

Contact Info

Product

Resources

About